\nG\u00fcvenli ve etkili bir a\u015f\u0131 i\u00e7in genelde Faz I, II ve III \u015feklinde tan\u0131mlanan, \u00fc\u00e7 a\u015famal\u0131 bir test s\u00fcreci gerekir. Faz III, t\u00fcm ara\u015ft\u0131rma s\u00fcrecinin yakla\u015f\u0131k % 70\u2019ni kaplayan, en uzun ve masrafl\u0131 a\u015famad\u0131r.(1) Bu fazda \u00e7ok farkl\u0131 insan gruplar\u0131nda (cins, ya\u015f, etnik k\u00f6ken, e\u015f zamanl\u0131 hastal\u0131\u011f\u0131 olanlar vb.) a\u015f\u0131n\u0131n dozu, g\u00fcvenli\u011fi ve v\u00fccutta yarataca\u011f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n etkinli\u011fi ara\u015ft\u0131r\u0131l\u0131r. Denemeler s\u0131ras\u0131nda ger\u00e7ek a\u015f\u0131 yan\u0131nda baz\u0131 g\u00f6n\u00fcll\u00fclere tesirsiz ba\u015fka bir a\u015f\u0131 da (plasebo) vurulur. Bu iki grup aras\u0131ndaki fark b\u00fcy\u00fck (anlaml\u0131) ise a\u015f\u0131n\u0131n etkili oldu\u011funa karar verilir.<\/p>\n
Faz III a\u015f\u0131 testi i\u00e7in SARS-CoV-2 vir\u00fcs\u00fcyle hi\u00e7 kar\u015f\u0131la\u015fmam\u0131\u015f binlerce g\u00f6n\u00fcll\u00fc bulunmas\u0131 gerekir. Ayn\u0131 zamanda bu i\u015fi farkl\u0131 hastanelerde (ve hatta \u00fclkelerde) y\u00fcr\u00fctecek kalabal\u0131k bir sa\u011fl\u0131k ekibi kurulmal\u0131 ve \u00e7al\u0131\u015fmalar\u0131 koordine edilmelidir. Denemeye kat\u0131lan g\u00f6n\u00fcll\u00fclerde 12 ay boyunca belli aral\u0131klarla bir\u00e7ok t\u0131bbi kontrol\u00fcn yap\u0131lmas\u0131 laz\u0131md\u0131r. G\u00f6n\u00fcll\u00fclerin ya\u015fad\u0131\u011f\u0131 b\u00f6lgeler, hastal\u0131\u011f\u0131n yo\u011fun g\u00f6r\u00fcld\u00fc\u011f\u00fc yerler olmal\u0131d\u0131r. \u00c7\u00fcnk\u00fc g\u00f6n\u00fcll\u00fcler vir\u00fcsle kar\u015f\u0131la\u015fmaz ise a\u015f\u0131n\u0131n koruyuculu\u011fu anla\u015f\u0131lamayacakt\u0131r. Ayn\u0131 \u015fekilde, \u00fcretilen a\u015f\u0131 sadece birka\u00e7 ay s\u00fcren k\u0131sa s\u00fcreli bir ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011fl\u0131yorsa i\u015fe yaramayacakt\u0131r, \u00e7\u00fcnk\u00fc a\u015f\u0131y\u0131 ayn\u0131 ki\u015fiye senede 4-5 kere vurmak m\u00fcmk\u00fcn de\u011fildir. Mevsimsel grip a\u015f\u0131lar\u0131nda oldu\u011fu gibi hi\u00e7 olmazsa \u201cen az\u201d 6 ayl\u0131k g\u00fcvenilir bir koruma sa\u011flamal\u0131d\u0131r. A\u015f\u0131 uzun s\u00fcreli ama zay\u0131f bir koruma sa\u011fl\u0131yorsa yine i\u015fe yaramayacakt\u0131r \u00e7\u00fcnk\u00fc bu durumda vir\u00fcs bir\u00e7ok insan\u0131 infekte etmeyi s\u00fcrd\u00fcrecektir.<\/p>\n
A\u015f\u0131 denemelerinde hayal k\u0131r\u0131kl\u0131klar\u0131n\u0131n en fazla ya\u015fand\u0131\u011f\u0131 a\u015fama Faz III\u2019t\u00fcr, \u00e7\u00fcnk\u00fc denemeler art\u0131k binlerce insan \u00fczerinde yap\u0131ld\u0131\u011f\u0131 i\u00e7in, istatistiki olarak birbiriyle uyumlu ve anlaml\u0131 sonu\u00e7lar elde etmek daha g\u00fc\u00e7 hale gelecektir. \u00d6rne\u011fin a\u015f\u0131 doz ayar\u0131n\u0131n belirlenmesi \u00e7ok zahmetlidir. A\u015f\u0131da ne miktarda antijen bulunmal\u0131d\u0131r ki, kanda yeterli miktarda antikor \u00fcrettirebilsin? Gere\u011finden y\u00fcksek dozda a\u015f\u0131 uygulan\u0131rsa baz\u0131 g\u00f6n\u00fcll\u00fclerin (\u00f6r., \u00e7ok ya\u015fl\u0131lar\u0131n ve \u00e7ocuklar\u0131n) ya\u015fam\u0131 tehlikeye at\u0131lm\u0131\u015f olur. A\u015f\u0131 dozu d\u00fc\u015f\u00fck tutulursa bu kez de \u00fcretilen antikor miktar\u0131yla SARS-CoV-2\u2019ye kar\u015f\u0131 etkin bir koruma sa\u011flanamaz. S\u00f6zgelimi ya\u015fl\u0131larda ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131f oldu\u011fundan bir gen\u00e7 i\u00e7in yeterli olacak a\u015f\u0131 dozu onlarda etkisiz kalacakt\u0131r.<\/p>\n
Diyelim ki farkl\u0131 gruplar i\u00e7in doz ayarlar\u0131 saptand\u0131 bu kez de a\u015f\u0131ya kar\u015f\u0131 \u00fcretilen antikorlar\u0131n kan dola\u015f\u0131m\u0131nda ne s\u00fcreyle etkili oldu\u011funun \u00f6\u011frenilmesi gerek. Bunu i\u00e7in aylarca g\u00f6n\u00fcll\u00fclerdeki durumu izlemek laz\u0131md\u0131r. Bu arada kimi zaman bir doz a\u015f\u0131n\u0131n yeterli olmad\u0131\u011f\u0131 da g\u00f6r\u00fclebilir ve hepatit B a\u015f\u0131s\u0131 gibi arayla en az iki doz a\u015f\u0131 yap\u0131lmas\u0131 gerekebilir. Ya da etkisi 4-5 y\u0131l s\u00fcrmeyen bir ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 olu\u015fuyorsa belki de grip a\u015f\u0131lar\u0131 gibi COVID-19 a\u015f\u0131s\u0131n\u0131n da tek doz ama her y\u0131l vurulmas\u0131 gerekebilir. Antikor \u00f6l\u00e7\u00fcmleri i\u00e7in deney protokollerinin de iyi haz\u0131rlanmas\u0131 laz\u0131md\u0131r. A\u015f\u0131dan daha da \u00f6nemlisi v\u00fccutta \u00fcretilen antikorun \u201cger\u00e7ek vir\u00fcse kar\u015f\u0131\u201d ne kadar etkili oldu\u011funun antijen-antikor ba\u011flanma deneyleriyle saptanmas\u0131 gerek. V\u00fccudu infekte etmi\u015f vir\u00fcs\u00fc etkisiz hale getirmeyen antikor i\u015fe yaramayacakt\u0131r.<\/p>\n
Oxford A\u015f\u0131 Grubu testleri<\/strong> \u00dcniversitenin yak\u0131n\u0131ndaki ve \u0130ngiltere\u2019deki baz\u0131 hastanelerde haz\u0131r olan birka\u00e7 grupla Faz I (18-55 ya\u015f aras\u0131 510 ki\u015fi) ve Faz II (55 ya\u015f \u00fcst\u00fc) denemelerine Nisan 2020\u2019den itibaren ba\u015flanm\u0131\u015ft\u0131r. Haziran\u2019\u0131n \u00fc\u00e7\u00fcnc\u00fc haftas\u0131na kadar (Faz 1-II-III gruplar\u0131 dahil) toplam 2500 g\u00f6n\u00fcll\u00fcye a\u015f\u0131 vurulmu\u015ftur ve izlemeleri s\u00fcrmektedir. Testlere kat\u0131lacak toplam g\u00f6n\u00fcll\u00fc say\u0131s\u0131 ise yakla\u015f\u0131k 10.500 olarak tasarlanm\u0131\u015ft\u0131r (\u00e7ocuklar bu say\u0131ya dahil de\u011fildir).(2,3) Bu arada Brezilya ve G\u00fcney Afrika da Oxford A\u015f\u0131 Grubu\u2019nun denemelerine kat\u0131lm\u0131\u015ft\u0131r.<\/p>\n \u00d6n\u00fcm\u00fczdeki sonbahar \u00e7\u0131kacak a\u015f\u0131 hakk\u0131nda\u2026<\/strong> 1) Hi\u00e7bir ters sonu\u00e7 \u00e7\u0131kmamas\u0131 ve Faz III testlerinde a\u015f\u0131n\u0131n vir\u00fcse kar\u015f\u0131 g\u00fcvenli ve etkili bir koruma sa\u011flad\u0131\u011f\u0131n\u0131n g\u00f6r\u00fclmesi. Bu acil durum plan\u0131nda, testlerin gelecek y\u0131l\u0131n sonuna do\u011fru \u00e7\u0131kacak kesin bilimsel sonu\u00e7lar\u0131n\u0131n beklenmeyece\u011fi anla\u015f\u0131lmaktad\u0131r.<\/p>\n 2) Testler s\u00fcrerken, \u00fcretici firman\u0131n (AstraZeneca) milyonlarca dozluk a\u015f\u0131y\u0131 haz\u0131r etmesi.<\/p>\n G\u00f6r\u00fcld\u00fc\u011f\u00fc gibi bu plan, normalde y\u0131llarca s\u00fcren ve \u00e7o\u011fu durumda ba\u015far\u0131l\u0131 olamayan standart a\u015f\u0131 geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131n\u0131n epey h\u0131zland\u0131r\u0131lm\u0131\u015f, riski y\u00fcksek bir versiyonu. \u015eayet olur da, Eyl\u00fcl\u2019de a\u015f\u0131n\u0131n haz\u0131r oldu\u011fu haberi \u00e7\u0131karsa bu a\u015f\u0131, testleri uygun \u015fekilde yap\u0131lm\u0131\u015f bir a\u015f\u0131 olmaktan \u00e7ok \u201c\u00e7aresizli\u011fin zorlad\u0131\u011f\u0131\u201d aceleye gelmi\u015f bir a\u015f\u0131 olacakt\u0131r. \u015eayet bu a\u015f\u0131n\u0131n insanlara hemen vurulmas\u0131na karar verilirse, kimi sa\u011fl\u0131k risklerinin hatta ya\u015fam kay\u0131plar\u0131n\u0131n g\u00f6ze al\u0131nd\u0131\u011f\u0131 anla\u015f\u0131lacakt\u0131r.<\/p>\n En yeni makale<\/strong><\/p>\n Oxford A\u015f\u0131 Grubu\u2019nun The Lancet dergisinde 20 Temmuz 2020 tarihinde online olarak yay\u0131mlad\u0131\u011f\u0131 en son bulgulara g\u00f6re, 23 Nisan ve 21 May\u0131s 2020 tarihleri aras\u0131nda, \u201c18-55 ya\u015f grubuna dahil, sa\u011fl\u0131kl\u0131\u201d 1077 kat\u0131l\u0131mc\u0131 ile y\u00fcr\u00fct\u00fclen a\u015f\u0131 test denemelerinden olumlu sonu\u00e7lar al\u0131nm\u0131\u015ft\u0131r. Bu denek grubunda a\u015f\u0131n\u0131n g\u00fcvenli ve imm\u00fcnogenik oldu\u011fu belirlenmi\u015ftir. Ergin g\u00f6n\u00fcll\u00fclerden g\u00fcvenilir bilgiler elde edildikten sonra denemelere \u00e7ocuklar da al\u0131nacakt\u0131r.(4) \u00c7ok daha fazla say\u0131da ve farkl\u0131 nitelikte denekte ayn\u0131 sonu\u00e7lar elde edilirse Oxford a\u015f\u0131s\u0131 yar\u0131\u015fta ipi g\u00f6\u011f\u00fcsleyebilir. Fakat 55 ya\u015f \u00fcst\u00fcnde ve farkl\u0131 co\u011frafi ve etnik gruplarda h\u00e2lihaz\u0131rda y\u00fcr\u00fct\u00fclen denemelerin Faz III\u2019\u00fcn en zorlu a\u015famas\u0131 oldu\u011fu da ak\u0131lda tutulmal\u0131. Hepsi ayn\u0131 t\u00fcre dahil olsa da, g\u00f6zleri, sa\u00e7lar\u0131, y\u00fcz\u00fc, derisi gibi molek\u00fcllerinde de k\u00fc\u00e7\u00fck farkl\u0131l\u0131klar\u0131 olan 7,8 milyar farkl\u0131 insan ya\u015famaktad\u0131r d\u00fcnyada.<\/p>\n A\u015f\u0131 \u00fcretimi a\u015famas\u0131<\/strong> A\u015f\u0131 balonlar\u0131<\/strong> Amerikan biyoteknoloji firmas\u0131 Moderna 18 May\u0131s 2020\u2019de yay\u0131nlad\u0131\u011f\u0131 bas\u0131n bildirisinde a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda olduk\u00e7a olumlu haberler vermi\u015f fakat herhangi bir ara\u015ft\u0131rma bulgusu aktarmam\u0131\u015ft\u0131. Bildiri, a\u015f\u0131 yolda diye bas\u0131nda sahte bir umut yarat\u0131lmas\u0131na yol a\u00e7m\u0131\u015f ve borsay\u0131 canland\u0131rm\u0131\u015ft\u0131. Oysa 14 Temmuz\u2019da The New England Journal of Medicine dergisinde firma ara\u015ft\u0131rmac\u0131lar\u0131n\u0131n yay\u0131mlad\u0131\u011f\u0131 raporda g\u00f6r\u00fcld\u00fc ki May\u0131s\u2019ta u\u00e7urulan haber, mRNA SARS-CoV-2 a\u015f\u0131s\u0131n\u0131n sadece 45 ki\u015fiyle yap\u0131lan Faz I denemelerinin \u00f6n bulgular\u0131yd\u0131.(5)<\/p>\n A\u015f\u0131 koluma ne zaman vurulur?<\/strong> Uzman tahmini ise 2021 ortas\u0131ndan \u00f6nce a\u015f\u0131 i\u00e7in hi\u00e7bir ihtimal g\u00f6rm\u00fcyor.(1) Bu konuda zaman zaman g\u00f6nl\u00fcm\u00fcz\u00fc ok\u015fayacak ama temelsiz haberler duyulacakt\u0131r; bu nedenle WHO ve g\u00fcvenilir bilimcilerden gelecek bilgilere itibar etmek gerekir.<\/p>\n NOT:<\/strong> Haluk Ertan\u2019\u0131n Covid-19 salg\u0131n\u0131 konusundaki son durumu ve gelecekteki olas\u0131 geli\u015fmeleri b\u00fct\u00fcn boyutlar\u0131yla ele alan geni\u015f yaz\u0131s\u0131 Bilim ve Gelecek\u2019in A\u011fustos say\u0131s\u0131nda yay\u0131nlanacak.<\/p>\n KAYNAKLAR:<\/strong> COVID-19 salg\u0131n\u0131 d\u00fcnyay\u0131 gittik\u00e7e daha fazla zorlamaya ba\u015flay\u0131nca a\u015f\u0131 konusu, \u00fczerinde en fazla spek\u00fclasyon yap\u0131lan ba\u015fl\u0131klardan biri haline geldi. \u0130nsanlar \u015fu anda ara\u015ft\u0131rma laboratuvarlar\u0131nda a\u015f\u0131n\u0131n icad\u0131yla, a\u015f\u0131n\u0131n koluna vurulaca\u011f\u0131 tarihi birbirine kar\u0131\u015ft\u0131rm\u0131\u015f halde. Bas\u0131nda dola\u015fan bu y\u0131la ait tarihlerin b\u00fcy\u00fck b\u00f6l\u00fcm\u00fc a\u015f\u0131n\u0131n bulunaca\u011f\u0131n\u0131 tahmin eden tarihler. A\u015f\u0131n\u0131n kolunuza eri\u015fmesi ise bundan ancak aylar sonra olacakt\u0131r. […]<\/p>\n","protected":false},"author":479,"featured_media":45818,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19],"tags":[2777,5848,5764,5827,6923],"class_list":["post-45816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-bilim-gundemi","tag-asi","tag-covid-19","tag-salgin","tag-sars-cov-2","tag-who"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t
\nWHO\u2019nun bildirdi\u011fine g\u00f6re, \u015fu anda \u00fczerinde \u00e7al\u0131\u015f\u0131lan 140\u2019a yak\u0131n a\u015f\u0131 aday\u0131ndan \u00e7ok b\u00fcy\u00fck b\u00f6l\u00fcm\u00fc hen\u00fcz Faz I ve II denemelerindedir. Bunlardan Faz III a\u015famas\u0131na ge\u00e7enlerin say\u0131s\u0131 23\u2019t\u00fcr. S\u00f6zgelimi a\u015f\u0131 yar\u0131\u015f\u0131n\u0131n en \u00f6n grubunda bulunan ve Faz III\u2019e ge\u00e7en Oxford \u00dcniversitesi denemeler i\u00e7in uygun g\u00f6n\u00fcll\u00fclerin se\u00e7imine devam etmektedir. \u00d6rne\u011fin, 22 Haziran 2020 tarihli G\u00f6n\u00fcll\u00fc Bilgilendirme Formu\u2019nda g\u00f6r\u00fcld\u00fc\u011f\u00fc kadar\u0131yla, 2. a\u015f\u0131 dozunun uygulanaca\u011f\u0131 Gruplar 5b, 5c (18-55 ya\u015f grubu) ve Grup 6 (18 \u00fcst\u00fc b\u00fct\u00fcn ya\u015f gruplar\u0131) i\u00e7in g\u00f6n\u00fcll\u00fc al\u0131m\u0131 halen devam etmekte ve kat\u0131l\u0131mc\u0131lara \u00e7al\u0131\u015fman\u0131n 12 ay s\u00fcrece\u011fi bildirilmektedir.(2) Yani testlerin gelecek y\u0131l\u0131n Haziran ortas\u0131na kadar s\u00fcrece\u011fi anla\u015f\u0131lmaktad\u0131r.<\/p>\n![\"\"](\"https:\/\/bilimvegelecek.com.tr\/wp-content\/uploads\/2020\/07\/2-9-300x152.jpg\")
\nOysa son birka\u00e7 ayd\u0131r bas\u0131nda proje liderlerinden Prof. Sarah Gilbert\u2019in a\u00e7\u0131klamalar\u0131na dayanarak Oxford \u00dcniversitesi\u2019nin Eyl\u00fcl 2020\u2019de a\u015f\u0131y\u0131 haz\u0131r edebilece\u011fi haberleri \u00e7\u0131k\u0131yor. Umuda a\u00e7 insanlara bas\u0131n konuyu yine a\u00e7\u0131k \u015fekilde aktarmamaktad\u0131r ne yaz\u0131k ki. A\u015f\u0131ya resmi onay al\u0131nabilmesi i\u00e7in yukar\u0131da ana hatlar\u0131 verilen 12 ayl\u0131k Faz III deneme takviminin mutlaka kurala uygun \u015fekilde tamamlanmas\u0131 gerekmektedir. Fakat durumun aciliyetinden dolay\u0131 a\u015f\u0131 geli\u015ftirme ekibi, testler devam ederken, ayn\u0131 zamanda, test edilen a\u015f\u0131n\u0131n be\u015f, on milyon dozluk \u00f6n \u00fcretimin de yap\u0131lmas\u0131na karar vermi\u015ftir. \u015eayet a\u015f\u0131n\u0131n \u00f6n klinik test sonu\u00e7lar\u0131 ba\u015far\u0131l\u0131 \u00e7\u0131karsa, en riskli gruplar\u0131n (\u00f6r., sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131 ve ya\u015fl\u0131lar\u0131n) a\u015f\u0131lanmas\u0131na, elde haz\u0131r olan bu a\u015f\u0131larla hemen ba\u015flanmas\u0131 planlanm\u0131\u015ft\u0131r. Bu ideal senaryonun ba\u015far\u0131s\u0131 iki etmene ba\u011fl\u0131:<\/p>\n![\"\"](\"https:\/\/bilimvegelecek.com.tr\/wp-content\/uploads\/2020\/07\/3-9-300x169.jpg\")
\n\u0130nsan denemeleri tamamland\u0131ktan ve sonu\u00e7lar\u0131n istatistik analizi bittikten sonra, g\u00fcvenli ve sa\u011flam bir koruma sa\u011flad\u0131\u011f\u0131na karar verilirse, a\u015f\u0131n\u0131n b\u00fcy\u00fck \u00f6l\u00e7ekli \u00fcretimine ge\u00e7ilebiliyor normal ko\u015fullarda. Bu i\u015f i\u00e7in \u00e7o\u011fu \u00f6zel sekt\u00f6re ait b\u00fcy\u00fck a\u015f\u0131 firmalar\u0131yla anla\u015f\u0131lmas\u0131 laz\u0131md\u0131r. Bu firmalar\u0131n bir\u00e7ok devlet ve sa\u011fl\u0131k kurumuyla onlarca a\u015f\u0131 i\u00e7in h\u00e2lihaz\u0131rda imzalanm\u0131\u015f, uzun vadeli anla\u015fmalar\u0131 vard\u0131r. \u015eayet \u00fcreticiyle anla\u015fmaya var\u0131l\u0131rsa firman\u0131n \u00fcretim platformlar\u0131n\u0131, SARS-CoV-2 a\u015f\u0131s\u0131 i\u00e7in, ba\u015ftan sonra haz\u0131rlamas\u0131 gerekecektir. Buradaki en \u00f6nemli sorun bu firmalar\u0131n istedikleri ticari garantinin kendilerine verilmesidir. \u00c7\u00fcnk\u00fc ge\u00e7mi\u015fte oldu\u011fu gibi kimi salg\u0131nlar birka\u00e7 y\u0131l i\u00e7inde g\u00fc\u00e7 kaybedip h\u0131z kesince, siyaset\u00e7iler ve sa\u011fl\u0131k kurumlar\u0131 art\u0131k ihtiya\u00e7 kalmad\u0131 diye a\u015f\u0131 sipari\u015flerini iptal edebilirler. Bu riskten kendilerini korumak zorunda olan firmalar sa\u011flam mali g\u00fcvenceler isterler. WHO bu s\u0131ralar t\u00fcm taraflar\u0131n birlikte uyumlu \u00e7al\u0131\u015fmas\u0131 i\u00e7in b\u00fcy\u00fck bir \u00e7aba i\u00e7indedir.<\/p>\n
\n\u015eu anda farkl\u0131 \u00fclkelere ve ara\u015ft\u0131rma laboratuvarlar\u0131na ait 100\u2019den fazla a\u015f\u0131 aday\u0131 \u00fczerine \u00e7al\u0131\u015fmalar s\u00fcrmektedir ve hangilerinin ipi g\u00f6\u011f\u00fcsleyece\u011fi hen\u00fcz belli de\u011fildir. A\u015f\u0131y\u0131 bulma olas\u0131l\u0131\u011f\u0131 en y\u00fcksek olan ara\u015ft\u0131rma ekipleri, \u00e7e\u015fitli a\u015f\u0131 \u00fcreticileriyle patent ve \u00fcretim ba\u011flant\u0131lar\u0131n\u0131 \u00e7oktan yapm\u0131\u015f haldeler. Baz\u0131 \u00fcniversitelere ve \u00f6zel sekt\u00f6re ait a\u015f\u0131 ara\u015ft\u0131rma ekipleri, ba\u015f\u0131 s\u0131k\u0131\u015fm\u0131\u015f h\u00fck\u00fcmetlerden para koparabilmek i\u00e7in, aylar \u00f6nceden a\u015f\u0131yla ilgili pek de ger\u00e7ek\u00e7i olmayan vaatlerde bulunmu\u015flard\u0131r. Bu, becerikli ve iyi bilimcilerin zaman zaman ba\u015fvurdu\u011fu bir y\u00f6ntemdir ama para ara\u015ft\u0131rmaya gidece\u011fi i\u00e7in bunu ele\u015ftirilecek bir \u015fey olarak g\u00f6rmemek gerek. Fakat bu arada ne yaz\u0131k ki a\u015f\u0131 \u00fcretimini yapacak firmalar\u0131n \u00e7o\u011funun hisseleri borsada i\u015flem g\u00f6rd\u00fc\u011f\u00fc i\u00e7in, \u015fimdiden bu \u00f6nemli sa\u011fl\u0131k konusunda kimi ger\u00e7ek d\u0131\u015f\u0131 haberler bas\u0131na s\u0131zd\u0131r\u0131lmaya ba\u015flam\u0131\u015ft\u0131r.<\/p>\n
\nA\u015f\u0131 konusuna ba\u015flarken s\u00f6yledi\u011fimiz kritik soruya geri d\u00f6n\u00fcl\u00fcrse yani bu yaz\u0131y\u0131 okuyabilecek kadar sa\u011fl\u0131kl\u0131 olanlar\u0131n koluna vurulacak a\u015f\u0131 ne zaman haz\u0131r olur? D\u00fcnya n\u00fcfusu 7,8 milyar ki\u015fi ve \u00e7ok kaba bir hesapla o zamana kadar bunun sadece 500 milyonunun vir\u00fcsle kar\u015f\u0131la\u015ft\u0131\u011f\u0131 kabul edilse, geriye 7,3 milyar ki\u015fi kal\u0131r. Bebekler ve a\u015f\u0131 vurulamayacak olanlar toplamdan \u00e7\u0131kar\u0131l\u0131rsa en az 6 milyar ki\u015fi a\u015f\u0131 talep edecektir \u015fayet a\u015f\u0131n\u0131n bir dozu yeterli gelirse. Bu miktarda a\u015f\u0131n\u0131n \u00fcretimi, da\u011f\u0131t\u0131m\u0131, kola vurulmas\u0131 herhalde aylar alacakt\u0131r.<\/p>\n
\n1) Amanat, F. ve Krammer, F., (2020). doi:10.1016\/j.immuni.2020.03.007.
\n2)https:\/\/covid19vaccinetrial.web.ox.ac.uk\/files\/cov002pisages18-55yearsbirminghamv6022jun20pdf (eri\u015fim 21\/07\/2020)
\n3) https:\/\/covid19vaccinetrial.web.ox.ac.uk\/blog-how-long-will-it-take-get-oxford-vaccine-deployment (eri\u015fim 21\/07\/2020)
\n4) Folegatti, PM ve ark., (2020). The Lancet. DOI:10.1016\/S0140-6736(20)31604-4
\n5) Jackson, LA ve ark., (2020). DOI: 10.1056\/NEJMoa2022483.<\/p>\n","protected":false},"excerpt":{"rendered":"